Skip to main content
Clinical Trials/NCT03951714
NCT03951714CompletedNot Applicable

12-wks Randomised Controlled Trial to Explore the Effect of a Smartphone App. Connected to an Add-on Device System Fitted on pMDI Inhaler on Adherence to Medications Intake and Clinical Outcomes in Difficult-to-treat Asthmatic Patients

Chiesi Farmaceutici S.p.A.1 site in 1 country160 target enrollmentStarted: August 12, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
160
Locations
1
Primary Endpoint
Change from Baseline in adherence rate to entire treatment period

Study Overview

Brief Summary

The purpose of this Study is to assess the effect of a smartphone application connected to an add-on device system fitted on Pressured Metered Dose Inhaler (PMDI) on adherence to take medications as prescribed and clinical outcomes in difficult-to-treat asthmatic patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient's written informed consent obtained prior to any study-related procedures
  • Male or female patient aged 18 years and above
  • Patient with established diagnosis of asthma for at least 6 months
  • Patient on maintenance therapy (Fixed dose combination ICS/LABA) with high dose of ICS
  • Patient with ACT score <20 at screening and at randomization
  • Non- or ex-smoker who smoked ≤ 10 Pack-years prior to screening
  • Patient must have their own Android® or iPhone operating system (IOS) smartphone
  • Ability to use the pMDI device correctly

Exclusion Criteria

  • Patient with an asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 to 3 month prior to screening
  • Patient with a history of near-fatal asthma
  • Clinically relevant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, psychiatric or any other disorder that would put the safety of the subject at risk through participation, or which would affect the analysis
  • Patient not able to be compliant with the study requirements.
  • Patient with a BMI > 40
  • Patient working on night shifts
  • Patient participating in the clinical phase of an interventional trial or have done so within the last 30 days prior to screening.
  • Patient who has an already planned major surgery or hospitalization
  • Female patient who is pregnant or lactating or who plans to become pregnant in the next 4 months.
  • Patient with a history of hypersensitivity to any of the components of Foster pMDI

Arms & Interventions

Reference

Other

Control experience using marketed application to record medication intake without reminders from the app

Intervention: Marketed experience application on adherence (Behavioral)

Intervention

Experimental

Full experience using marketed application, with all functionalities enabled

Intervention: Marketed experience application on adherence (Behavioral)

Outcomes

Primary Outcomes

Change from Baseline in adherence rate to entire treatment period

Time Frame: From baseline to end of participation (up to 3 months)

Adherence Rate of doses correctly taken twice daily

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials